使用合成RAS激活癌症杀死系统向RAS突变癌细胞
Fei Teng1, Qingqin Gao2, Li Zhou2
1Medical School, University of Chinese Academy of Sciences, Beijing 100049, China.
Trends in biotechnology
|August 30, 2025
概括
一种新型RAS激活癌症杀死 (RACK) 系统向并消除RAS突变癌细胞,即使是那些对常规疗法的抵抗力. 这种合成平台为以前无法治疗的癌症提供了一种新方法.
科学领域:
- 癌症学
- 分子生物学
- 药物发现
背景情况:
- 瘤性RAS蛋白在癌症中经常发生突变,但仍然是难以达到的药理目标.
- 目前的癌症疗法常常与获得的抗药性和有效向特定突变作斗争.
研究的目的:
- 开发一种新型合成平台,用于向识别和消除RAS突变癌细胞.
- 创建一个能够克服抵抗机制的系统, 并针对广泛的致癌突变.
主要方法:
- 开发一种RAS激活的杀死癌症 (RACK) 系统,使用一种高度特定的转录传感器来检测瘤RAS信号.
- 在体外测试RACK对各种RAS和非RAS突变物 (KRAS,NRAS,BRAF,RTK) 的疗效.
- 使用异种移植模型,包括对常规抑制剂耐药的模型,评估RACK的 in vivo性能.
主要成果:
- 在RAS突变的癌细胞中,RACK具有强大和特定的向性.
- 该系统对具有耐药性的癌细胞保持有效性,优于现有的抑制剂.
- 在体内研究显示选择性抑制RAS突变瘤生长,包括对异位基因特异抑制剂耐药的模型.
结论:
- RACK系统代表了检测和治疗RAS突变癌症的开创性药物方法.
- RACK的模块化设计允许优化和广泛应用.
- 这个平台提供了一个有前途的策略来应对目前无法治疗的癌症目标.
更多相关视频
05:45In Vitro Establishment of a Genetically Engineered Murine Head and Neck Cancer Cell Line using an Adeno-Associated Virus-Cas9 System
Published on: January 9, 2020
8.0K
07:40A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions
Published on: May 27, 2021
4.3K
相关概念视频
The Ras Gene
6.4K
The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
Ras is a...
6.4K
Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
Abnormal Proliferation
4.6K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.6K
Small GTPases - Ras and Rho
4.2K
Ras and Rho are small monomeric GTPases that act downstream of receptor tyrosine kinase (RTK) and regulate various cellular processes. These GTPases switch between active and inactive states by binding to guanine nucleotides.
Three regulatory proteins control their activity:
Three regulatory proteins control their activity:
4.2K
mTOR Signaling and Cancer Progression
3.9K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.9K
MAPK Signaling Cascades
6.0K
Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
6.0K
